X

Drug Profile

CTI 01

Alternative Names: Ethyl pyruvate; Ethyl pyruvate compound

Latest Information Update: 06 Feb 2014

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Critical Therapeutics
Class Anti-inflammatories; Cytoprotectives
Mechanism of Action Free radical scavengers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Shock

Most Recent Events

04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
19 Sep 2006 Results from a phase II clinical trial have been added to the adverse events and Vascular therapeutic trials sections
22 Mar 2006 Suspended - Phase-II for Shock in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com